-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Izotropic's Breast CT Radiation Imaging Subsystem Powered on and Takes Initial Images
Izotropic's Breast CT Radiation Imaging Subsystem Powered on and Takes Initial Images
VANCOUVER, BC - TheNewswire - November 22, 2021 - Izotropic Corporation ("Izotropic" or the "Company") (CNSX:IZO.CN) (OTC:IZOZF) (FSE:1R3), a Company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers provides updates on the following:
- IzoView radiation imaging subsystem assembly, functionality, and installation features
- Formal radiation safety certification
- Initial phantom image acquisition and image reconstruction software
Izotropic is pleased to announce that its engineering teams have successfully built and assembled IzoView's radiation imaging subsystem, and it has been formally certified as safe to operate. This milestone enables the subsystem, which is now taking static images, to be characterized and optimized for 360-degree image acquisition.
Radiation Imaging Subsystem: Safety and minimized installation costs
IzoView's radiation imaging subsystem has been powered on, tested, and emits less radiation into the surrounding area than diagnostic mammography. A formal radiation safety certification was awarded upon completion of radiation safety testing that was conducted by the governing health authority.
Radiation safety testing is completed by measuring the amount of radiation output into the surrounding area or imaging suite during a single scan. Radiation-based imaging devices typically require a radiation-safe leaded room or a leaded divider for the technician to stand behind during the scan. Certain levels of radiation leakage that result from radiation-based imaging devices into the imaging suite are allowable under standard safety requirements, but measures must be taken to protect patients and staff with increased installation and set up costs to the customer. IzoView has been designed with specific features to minimize customer installation and shielding costs while providing enhanced patient and technician safety.
IzoView's Initial Images
The radiation imaging subsystem is now acquiring and producing preliminary images. Images have been taken using different types of phantoms which are stand-in objects in place of human tissue. Phantoms have been used to calibrate the imaging system in relation to the detector and the geometry of the imaging system for the 3D reconstruction software.
With this milestone achieved, engineering teams can now begin optimizing and calibrating the imaging subsystem to acquire images in 360 degrees- the key differentiator for IzoView's true 3D images versus 2D mammography or tomosynthesis images.
The preliminary image data being produced will support the advancement of the new image reconstruction software that utilizes deep machine learning algorithms currently in development in partnership with Johns Hopkins University School of Medicine.
Phantom image acquisition, which was initially projected to begin in Q1 2022, has begun ahead of schedule.
Messages from CEO and EVP of Product Engineering
"This next stage is really about fine-tuning key variables in our hardware and software upgrades as they work together to create the high-resolution 3D images our Breast CT system offers," said Dr. Younes Achkire, Executive Vice President of Product Engineering. "We're doing this so when we ramp up to production for our clinical study units, our images and device operation will be 100% consistent."
CEO, Dr. John McGraw, stated: "Even with ongoing global supply chain issues, we have our key components: generator, power unit, detector, and computer, and we can power it all on and produce images. I'm very proud of what we're continuing to accomplish at Izotropic."
ON BEHALF OF THE BOARD
For investor relations inquiries, contact:
James Berard
Email: jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures and will initiate in Q2 2022. In follow-on clinical studies, Izotropic intends to validate platform applications including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com
Forward-Looking Statements
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind.
Copyright (c) 2021 TheNewswire - All rights reserved.
温哥华,公元前-新闻通讯社-2021年11月22日-各向同性公司("各向同性“或”公司") (CNSX:以藏。氯化萘)(场外交易:IZOZF)(FSE:1R3), 一家公司将专用乳腺CT(计算机断层扫描)成像平台IzoView商业化,以便更准确地检测和诊断乳腺癌,提供了以下方面的最新信息:
-IzoView辐射成像子系统组件、功能和安装特性
-正式的辐射安全认证
-初始模型图像采集和图像重建软件
Izotroy公司高兴地宣布,它的工程团队已经成功地建造和组装了IzoView的辐射成像子系统,并且它已经被正式认证为可以安全操作。这一里程碑使目前正在拍摄静态图像的子系统能够针对360度图像采集进行特征化和优化。
辐射成像子系统:安全性和最低安装成本
IzoView的辐射成像子系统已经开机、测试,向周围区域发射的辐射比诊断性乳房X光检查要少。在完成由主管卫生当局进行的辐射安全测试后,颁发了正式的辐射安全证书。
辐射安全测试是通过测量单次扫描期间输出到周围区域或成像套件的辐射量来完成的。基于辐射的成像设备通常需要一个防辐射的引线房间或引线隔板,以便技术人员在扫描期间站在后面。根据标准安全要求,基于辐射的成像设备进入成像套件所导致的一定程度的辐射泄漏是允许的,但必须采取措施保护患者和工作人员,增加安装,并增加客户的设置成本。IzoView的设计具有特定功能,可将客户安装和屏蔽成本降至最低,同时提高患者和技术人员的安全性。
IzoView的初始图像
辐射成像子系统现在正在采集和产生初步图像。已经使用不同类型的模体来拍摄图像,这些模体是代替人体组织的替身对象。已经使用模体相对于探测器和3D重建软件的成像系统的几何形状来校准成像系统。
随着这一里程碑的实现,工程团队现在可以开始优化和校准成像子系统,以获得360度的图像-这是IzoView真正的3D图像与2D乳房X光检查或断层合成图像的关键区别。
正在制作的初步图像数据将支持新图像重建软件的发展,该软件利用目前正在与约翰·霍普金斯大学医学院合作开发的深度机器学习算法。
幻影图像采集最初计划于2022年第一季度开始,现在已经提前开始。
来自首席执行官兼产品工程执行副总裁的信息
产品工程部执行副总裁尤尼斯·阿奇基尔博士说:“下一阶段实际上是对硬件和软件升级中的关键变量进行微调,因为它们将共同创建我们的乳房CT系统提供的高分辨率3D图像。”我们这样做是为了当我们的临床研究单位逐步投产时,我们的图像和设备操作将百分之百一致。“
首席执行官约翰·麦格劳博士说:“尽管全球供应链问题仍在继续,但我们有我们的关键部件:发电机、动力装置、探测器和计算机,我们可以为它们通电并生成图像。我为我们在Izotroal公司继续取得的成就感到非常自豪。”
我代表董事会
有关投资者关系的查询,请联系:
电子邮件:jberard@izocorp.com
电话:778-228-2314
免费电话:1-833-IZOCORP分机1
关于Izotroal公司
Izotroy公司是唯一一家将专用乳腺CT成像平台IzoView商业化的上市公司,该平台用于更准确地检测和诊断乳腺癌。为了加快患者和供应商使用IzoView的速度,Izotroy的初步临床研究打算证明诊断性乳房CT成像的性能优于诊断性乳房X光检查程序,并将于2022年第二季度启动。在后续的临床研究中,Izotrotic公司打算验证平台应用,包括放射学中的乳房筛查、外科肿瘤学中的治疗计划和监测,以及整形和重建外科中的乳房重建和植入物监测。
欲了解有关Izotroy公司的更多信息,请访问该公司的网站:izocorp.com。并通过在SEDAR上查看其个人资料Sedar.com
前瞻性陈述
本文件可能包含“前瞻性陈述”,这些陈述基于对公司管理层、业务的当前估计、假设、预测和预期,以及对公司运营所处的相关市场和经济环境的了解。在可能的情况下,公司已尝试通过使用诸如“预期”、“相信”、“设想”、“估计”、“预期”、“打算”、“可能”、“计划”、“预测”、“计划”、“预测”、“项目”、“目标”、“潜在”、“将会”、“将会”、“可能”、“应该”、“继续”等词语来识别此类信息和陈述。关于未来事件、趋势或前景或未来经营或财务表现的任何讨论,“设想”及其他类似表述及其派生,尽管并非所有前瞻性表述都包含这些识别词汇。这些陈述不是对业绩的保证,涉及难以控制或预测的风险和不确定因素,因此,它们可能导致公司未来活动的结果与此类陈述的内容和影响大不相同。前瞻性陈述仅在作出之日起具有相关性,除非法律另有要求,否则公司没有义务更新或修改任何前瞻性陈述,以反映新信息或未来事件或情况的发生。本公司及其股东、高级管理人员和顾问均不对任何人根据本文包含的信息采取的任何行动以及任何行动的结果负责,包括但不限于购买或出售公司证券。本文档中的任何内容都不应被视为任何类型的医疗或其他建议。
版权所有(C)2021 TheNewswire-保留所有权利。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧